Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02264379
Other study ID # STR - Oli-P - 2014
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 2014
Est. completion date August 2021

Study information

Verified date February 2023
Source Technische Universität Dresden
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to evaluate the outcomes of patients treated with an high dose radiation regimen using either stereotactic hypofractionated or normofractionated radiotherapy for oligometastatic prostate cancer and to establish efficacy (producing a desired result or effect) and safety in this setting.


Description:

Study Groups: If the patient found to be eligible to take part in this study, the patient will be assigned to a study group based on the size of the lesion(s) and the discretion of the responsible physician. Up to 71 patients will be enrolled in the study. If the patient is treated with standard radiotherapy, the patient will receive 25 fractions of 2 Gy to the metastases, the treatment duration will be 5 weeks. If the patient is treated with image-guided hypofractionated radiotherapy, the patient will receive 3 fractions of 10 Gy to the metastases, the treatment duration will be 1 week. Radiation Planning and Treatment: During all radiation treatments, the images that are taken during the treatment will be closely analyzed after treatment is over. The patient will have 3 to 25 radiation treatments per metastasis depending on the discretion of the responsible physician. The rest of the radiation treatment planning and treatment delivery appointments will be unchanged. The dose given to the tumor and number of treatments the patient will receive, will be determined by the discretion of the responsible physician, and is not affected by taking part in this study. Follow-Up Visits: After the radiation treatment schedule ends, the patient will return for follow-up visits at the following time points: - At 3 months - Then, every 3 months for 1 year, and then - 1 time a year after that, for as long as possible Additional follow up visits may be scheduled, if the responsible physician thinks they are needed. At these visits, the following tests and procedures will be performed: - Any updates to the medical history of the patient will be recorded and the patient will be asked about any side effects the patient may be having. - The patient's performance status will be recorded. - The patient's complete symptom questionnaires will be reviewed. - The patient will have a clinical examination - The patient will have follow-up imaging (such as an MRI) to check the status of the disease. This is an observational study. Radiation therapy is delivered using CE-certified and commercially available methods.


Recruitment information / eligibility

Status Completed
Enrollment 73
Est. completion date August 2021
Est. primary completion date October 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient with good general condition (WHO 0-1) - No comorbidities which limit the further life expectancy of the patient to <5 years (opinion of the physician) - Histologically confirmed prostate cancer - State after definitive local therapy, such as radical prostatectomy or definitive radiotherapy (even after neo-/-adjuvant hormone therapy, after postoperative radiotherapy) - PSA relapse after primary therapy or radiological unique metastasis, present complete staging (up to 8 weeks old) by CT thorax/ abdomen/ pelvis and bone scan alternatively a hybrid imaging PET (positron emission tomography) (acetate PET, PET-PSMA, NAFL-PET) and CT / MRI is sufficient - Imaging detection of individual metastases (up to 5, depending on the situation) that a Radiation therapy are available (histological confirmation of the MET is not required) - No parallel participation to further clinical therapeutic trials to 4 weeks and after radiation - Consent of the patient and written informed consent Exclusion Criteria: - severe comorbidity which limit the further life expectancy of the patient to <5 years (opinion of the physician) - PSA in PSA relapse> 10ng/ml - Ongoing androgen deprivation at the time of study inclusion - not been carried out local therapy - no histological confirmation of prostate cancer - lack of compliance - absence of consent of the patient

Study Design


Intervention

Radiation:
normal fractionated irradiation
25*2 Gy (once a day, 5 days a week)
hypo fractionated irradiation
3*10 Gy (once a day, 2-3 days a week)

Locations

Country Name City State
Germany Technische Universität Dresden, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology Dresden Saxony
Germany Universitätsklinikum Tübingen, Department of Radiation Therapy and Radiation Oncology Tübingen

Sponsors (1)

Lead Sponsor Collaborator
Technische Universität Dresden

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Late Toxicity at year 2 after ablatvie radiotherapy The toxicity will be scored (CTCAE 4.03) at each follow up visit, the status will be recorded by clinical examination and radiological imaging. 24 months after therapy
Secondary Early toxicity The toxicity will be scored (CTCAE 4.03) at 3 months follow up visit, the status will be recorded by clinical examination and radiological imaging. until day 90 after start radiotherapy
Secondary Quality of life (QLQ-C30 and QLQ-PR25) during Follow-up QoL will be assessed with the QoL-Questionaires QLQ-C30 and QLQ-PR25 at baseline, 3, 12 and 24 months after treatment. 24 months after end of therapy
Secondary Local control of irradiated tumor manifestations The tumor response will be evaluated (RECIST) at follow up visit 3,12 and 24 months after end of treatment, the status will be recorded by clinical examination and radiological imaging. 24 months after end of therapy
Secondary Therapy-free survival Therapy-free survival will be assessed as time from start of radiation to start of systemic treatment or androgen deprivation. The status will be assessed at each follow-up visit. 24 months after end of therapy
Secondary PSA relapse-free survival PSA relapse-free survival will be assessed as time from start of radiation to PSA-rise more than 20% above baseline. PSA - value will be assessed by blood testing. 24 months after end of therapy
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A